Literature DB >> 29492674

Urinary CD80: a biomarker for a favorable response to corticosteroids in minimal change disease.

Gabriel Cara-Fuentes1, Miguel A Lanaspa2, Gabriela E Garcia3, Mindy Banks4, Eduardo H Garin5, Richard J Johnson3.   

Abstract

Minimal Change Disease (MCD) is the most common type of nephrotic syndrome in children. The etiology has remained unknown, although it is commonly thought to be due to an unknown circulating factor that triggers podocyte dysfunction. To date, several changes in podocytes have been reported in MCD, of which one is the expression of CD80, also known as B7.1, which is a costimulatory molecule that is normally expressed on antigen -presenting cells. Some studies suggest that subjects with steroid-sensitive MCD may express CD80 in their podocytes during relapse and that this expression is associated with high urinary levels of CD80. Indeed, subjects with MCD in remission, or subjects with other glomerular diseases, such as focal segmental glomerulosclerosis, have substantially lower levels of urinary CD80 excretion. A recent study has now reported that high levels of urinary CD80 may be a sensitive marker for steroid-sensitivity and that their presence is also associated with long-term preservation of renal function. Thus, urinary CD80 is emerging as a potential biomarker for steroid-responsiveness in children presenting with primary nephrotic syndrome.

Entities:  

Keywords:  CD80; Focal segmental glomerulosclerosis; Minimal change disease; Nephrotic syndrome

Mesh:

Substances:

Year:  2018        PMID: 29492674      PMCID: PMC5990433          DOI: 10.1007/s00467-018-3886-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

1.  Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome.

Authors:  Om P Mishra; Ravindra Kumar; Gopeshwar Narayan; Pradeep Srivastava; Abhishek Abhinay; Rajniti Prasad; Ankur Singh; Vineeta V Batra
Journal:  Pediatr Nephrol       Date:  2017-02-16       Impact factor: 3.714

2.  Podocytes are nonhematopoietic professional antigen-presenting cells.

Authors:  Andreas Goldwich; Miriam Burkard; Martha Olke; Christoph Daniel; Kerstin Amann; Christian Hugo; Christian Kurts; Alexander Steinkasserer; André Gessner
Journal:  J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 10.121

3.  Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.

Authors:  Eduardo H Garin; Wei Mu; John M Arthur; Christopher J Rivard; Carlos E Araya; Michiko Shimada; Richard J Johnson
Journal:  Kidney Int       Date:  2010-05-19       Impact factor: 10.612

4.  Urinary CD80 levels as a diagnostic biomarker of minimal change disease.

Authors:  Chen Ling; Xiaorong Liu; Ying Shen; Zhi Chen; Jianfeng Fan; Yeping Jiang; Qun Meng
Journal:  Pediatr Nephrol       Date:  2014-08-21       Impact factor: 3.714

5.  Role of podocyte B7-1 in diabetic nephropathy.

Authors:  Paolo Fiorina; Andrea Vergani; Roberto Bassi; Monika A Niewczas; Mehmet M Altintas; Marcus G Pezzolesi; Francesca D'Addio; Melissa Chin; Sara Tezza; Moufida Ben Nasr; Deborah Mattinzoli; Masami Ikehata; Domenico Corradi; Valerie Schumacher; Lisa Buvall; Chih-Chuan Yu; Jer-Ming Chang; Stefano La Rosa; Giovanna Finzi; Anna Solini; Flavio Vincenti; Maria Pia Rastaldi; Jochen Reiser; Andrzej S Krolewski; Peter H Mundel; Mohamed H Sayegh
Journal:  J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 10.121

6.  Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis.

Authors:  Rubina Novelli; Elena Gagliardini; Barbara Ruggiero; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nephron       Date:  2016-05-21       Impact factor: 2.847

7.  Urinary CD80 excretion increases in idiopathic minimal-change disease.

Authors:  Eduardo H Garin; Leila N Diaz; Wei Mu; Clive Wasserfall; Carlos Araya; Mark Segal; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 10.121

8.  Induction of B7-1 in podocytes is associated with nephrotic syndrome.

Authors:  Jochen Reiser; Gero von Gersdorff; Martin Loos; Jun Oh; Katsuhiko Asanuma; Laura Giardino; Maria Pia Rastaldi; Novella Calvaresi; Haruko Watanabe; Karin Schwarz; Christian Faul; Matthias Kretzler; Anne Davidson; Hikaru Sugimoto; Raghu Kalluri; Arlene H Sharpe; Jordan A Kreidberg; Peter Mundel
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-κB-dependent pathway.

Authors:  Michiko Shimada; Takuji Ishimoto; Pui Y Lee; Miguel A Lanaspa; Christopher J Rivard; Carlos A Roncal-Jimenez; David T Wymer; Hideaki Yamabe; Peter W Mathieson; Moin A Saleem; Eduardo H Garin; Richard J Johnson
Journal:  Nephrol Dial Transplant       Date:  2011-05-26       Impact factor: 5.992

10.  Tubular B7-1 expression parallels proteinuria levels, but not clinical outcomes in adult minimal change disease patients.

Authors:  Sung Woo Lee; Seon Ha Baek; Jin Ho Paik; Sejoong Kim; Ki Young Na; Dong-Wan Chae; Ho Jun Chin
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

View more
  3 in total

1.  Clinical significance of T lymphocyte subsets, immunoglobulin and complement expression in peripheral blood of children with steroid-dependent nephrotic syndrome/frequently relapsing nephrotic syndrome.

Authors:  Shulian Chen; Jianxin Wang; Shishan Liang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 2.  CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.

Authors:  Yoong Mond Teh; Soo Kun Lim; Norhana Jusoh; Kahar Osman; Siti Aisyah Mualif
Journal:  Biomed Res Int       Date:  2021-01-06       Impact factor: 3.411

3.  Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis.

Authors:  Masafumi Sugiyama; Saki Okuda; Yasuaki Hirooka
Journal:  Rheumatol Adv Pract       Date:  2022-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.